More stroke patients going home on Pradaxa. Pradaxa has warnings for extensive bleeding with reports of fatalities. Pradaxa lawyers see increase of Pradaxa related deaths from internal bleeding and Brain Hemmorhages. This MSW is very concerned about elderly on Pradaxa.
Feb 15, 2012
By: Anna D. Garrett, PharmD, BCPS
Drug Topics, pradaxa
Anna D. Garrett, PharmD, BCPS
A recent study indicates that 95% of stroke patients with atrial fibrillation (AF) received prescriptions for anticoagulants in 2010 if they were treated at hospitals participating in the Get With The Guidelines–Stroke (GWTG-Stroke) program. This rate is a 7% increase from 2003 data.
Researchers surveyed nearly 1,400 hospitals in the United States that participated in GWTG-Stroke. The study included almost 200,000 patients with AF, 47.6% of whom were eligible for treatment with anticoagulants. Hospitals with a higher volume of stroke patients, as well as academic hospitals, were more likely to send patients with AF home with anticoagulants.
The study showed that the number of patients ineligible to receive anticoagulants because of other problems, such as being at high risk for falls, dropped from 70% to 28%. Rates of anticoagulation were lower in women than in men (odds ratio [OR]=0.94). When compared with whites, African Americans and Hispanics were less likely to receive anticoagulation (OR=0.77 and OR=0.81, respectively), and patients with diabetes were less likely to be discharged on anticoagulation (OR=0.91), although use of anticoagulants increased across all groups.
The length of time in GWTG-Stroke was associated with improved anticoagulation use, although the study could not prove that the program was responsible for improvements. The authors note that improving use of anticoagulants among selected populations should be the focus of future efforts.
Source: Lewis WR, Fonarow GC, Grau-Sepulveda MV, et al. Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelines–Stroke. Am Heart J. 2011;162:692-699.e2.